Corrigendum to “Biological characterization of PM226, a chromenoisoxazole, as a selective CB<inf>2</inf> receptor agonist with neuroprotective profile” [Pharmacol. Res. (2016) 110(2016) (205–215)] (S1043661816302080) (10.1016/j.phrs.2016.03.021)

Título:	Corrigendum to “Biological characterization of PM226, a chromenoisoxazole, as a selective CB<inf>2</inf> receptor agonist with neuroprotective profile” [Pharmacol. Res. (2016) 110(2016) (205–215)] (S1043661816302080) (10.1016/j.phrs.2016.03.021)
Autores/as:	Gómez-Cañas, M. Morales, P. García-Toscano, L. Navarrete, C. Muñoz, E. Jagerovic, N. Fernández-Ruiz, J. García Arencibia, Moisés Pazos, M. R.
Clasificación UNESCO:	32 Ciencias médicas
Fecha de publicación:	2017
Editor/a:	1043-6618
Publicación seriada:	Pharmacological Research
Resumen:	© 2017 Elsevier LtdThe authors have realised that they failed to acknowledge the affiliation of author M. García-Arencibia to the “Grupo de Investigación en Medio Ambiente y Salud, Instituto Universitario de Investigaciones Biomédicas y Sanitarias, Universidad de Las Palmas de Gran Canaria, Spain” the affiliation had been mistakenly indicated as present address in the original article [1]. The Authors apologise for any inconvenience this may have caused.
URI:	http://hdl.handle.net/10553/36017
ISSN:	1043-6618
DOI:	10.1016/j.phrs.2017.04.002
Fuente:	Pharmacological Research [ISSN 1043-6618], v. 120, p. 302
Colección:	Artículos

Vista completa